JUNO has been the topic of a number of research reports. The value of the total investment in Juno Therapeutics, Inc. went from $821,000 to $1,285,000 increasing 56.5% for the reporting period. Moreover, Two Sigma Secs Ltd Liability has 0.09% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 15,925 shares. Analysts giving shares a rating of 1 or 2 would be indicating a Buy. Finally, BidaskClub downgraded shares of Juno Therapeutics from a buy rating to a hold rating in a research report on Saturday, June 10th. The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 1.90, which implies that analysts are generally bullish in their outlook for JUNO over the next year. At the time of writing, the First Call consensus price target for the company is $28.18. (NASDAQ JUNO) traded up 8.46% on Friday, reaching $45.14.
Higher-beta stocks tend to be more volatile and therefore riskier, but provide the potential for higher returns. STOR's total market worth is $4.83B. Shares of the company are trading at $45.12 significantly higher than $34.94, the 50 day moving average and much higher than the 200 day moving average of $27.48.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, August 3rd. After $-0.75 actual EPS reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 17.33% negative EPS growth. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million.
Institutional investors now hold around $3.44 billion or 85.3% in JUNO stock.
Shares of Juno Therapeutics, Inc. Wells Fargo initiated the stock with "Outperform" rating in Wednesday, February 22 report. If you are reading this story on another site, it was copied illegally and republished in violation of USA & worldwide copyright & trademark laws. Juno Therapeutics, Inc. The stock's 50 day moving average price is $34.94 and its 200-day moving average price is $27.48. Going toward to the 50-day, we can see that shares are now trading 34.10% off of that figure. Its weekly and monthly volatility is 0.80%, 1.16% respectively. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, July 13th. $37.69's average target is -18.37% below currents $46.17 stock price. The disclosure for this sale can be found here. Tightening the gaze, stock performance for the last 5 trading days is -6.70%.
Hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its position in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company's stock worth $102,000 after acquiring an additional 228 shares during the period. QS Investors LLC purchased a new stake in Juno Therapeutics in the 2nd quarter worth approximately $135,000. Amalgamated Bank raised its stake in shares of Juno Therapeutics by 19.0% during the second quarter.
Tightening the gaze, stock performance for the last 5 trading days is -3.71%.
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.